Efficacy and Safety of Hydrogen Therapy in Patients with Early-Stage Interstitial Lung Disease: A Single-Center, Randomized, Parallel-Group Controlled Trial.
In 87 patients with early-stage ILD, a significant decrease in CPI and improvement in DLCO-sb were observed in the hydrogen group compared with those in the control group. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human…
Read Article